Law360 | June 22, 2023
Rebecca B. Reingold, associate director of the O’Neill Institute for National and Global Health Law at the Georgetown University Law Center, said she thinks this case “will almost certainly reach the Supreme Court, regardless of the Fifth Circuit Court of Appeals’ pending decision.” And if the justices do take up the case, they “will determine how accessible mifepristone will be in the U.S. going forward,” Reingold told Law360.